The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and ...
Dupixent approved in China as the first-ever biologic medicine for patients with chronic obstructive pulmonary disease (COPD). September 27, 2024. Accessed September 27, 2024.
Dr MeiLan Han, a Professor of Medicine and Chief of the Division of Pulmonary and Critical Care at the University of Michigan Health, discusses the impact inadequately controlled COPD has on daily ...